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Abstract
Background: Accurate diagnosis of acute coronary syndrome (ACS) in a timely fashion is challenging in the elderly
population, especially elderly women, who usually exhibit atypical clinical symptoms. A multiple cardiac biomarker
(MCB) based approach has been shown to improve diagnostic efficacy of ACS. However, data in various age groups
and sex differences remain largely unexplored.
Methods: Point-of-care testing (POCT) was performed on 290 patients (aged ≥18 years) who were admitted to the
emergency department (ED) with symptoms of acute chest pain under suspicion of acute coronary syndrome (ACS).
The MCB approach in current work assessed four cardiac biomarkers: myoglobin, troponin I, creatine kinase-myocardial
band isoenzyme fraction (CK-MB), and brain natriuretic peptide (BNP).
Results: Overall, the MCB approach demonstrated considerably higher sensitivity for elderly patients than for younger
patients in identifying ACS (80.0 % [64.1–90.0] vs. 52.6 % [37.3–67.5] for ≥65 years and <65 years groups), with younger
population showed greater specificity (44.1 % [35.3–53.4] vs. 84.9 % [76.9–90.5] for ≥65 years and <65 years groups,
respectively). The highest sensitivity achieved for elderly women who reported chest pain was 87.5 % [95 % CI: 64–96.5]).
In general, the sensitivity of this approach was higher for female patients than for male patients (80 % [58.4–91.9] vs. 61 %
[47.8–73.0]).
Conclusions: The MCB approach can provide a quick and accurate clinical diagnosis in elderly and female patients, both
of whom have traditionally proven to be challenging to diagnose from suspected acute coronary syndrome.
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Background
Acute coronary syndrome (ACS) is an extremely common
condition that is one of the leading causes of death world-
wide. ACS is commonly encountered in the emergency
room and occurs most often in elderly patients [1, 2];
however, in recent years the average age of patients with
ACS has declined due to changes in lifestyle and personal
behavior.
Women who have ACS differ from their male counter-
parts both in terms of reported symptoms, clinical manifes-
tations and diagnosis rates [3–5]. In terms of symptoms
and clinical manifestations, female patients primarily ex-
hibit unstable angina and non-ST-segment elevation myo-
cardial infarction (NSTEMI), while male patients primarily
exhibit STEMI [3, 5]. Regarding diagnosis, biomarker sensi-
tivity and specificity in exercise tests have been reported to
be lower in both women and men [5].
Cardiac biomarkers for acute coronary syndrome play
key roles diagnosis, risk assessment, treatment, and supervi-
sion. Troponin I is a sensitive indicator of cardiomyocyte
necrosis and an important biomarker for monitoring treat-
ment. Myoglobin is the earliest biomarker of myocardial
injury to appear, allowing doctors to rule out the possibility
of myocardial infarction in a timely fashion. Apart from
diagnostic role in heart failure, brain natriuretic peptide
(BNP) is also closely related to acute coronary syndrome
[6]. However, when used individually, these biomarkers are
limited by several factors in clinical scenarios, especially in
elderly patients [2].
Owing to differences in the diagnostic ability and per-
formance of cardiac biomarkers across a wide range of
patient population with age and gender distributions,
and considering their important role in the diagnosis of
acute coronary syndrome, we currently examined the ac-
curacy of four cardiac biomarkers in the diagnosis of




From March to November 2009, patients who visited
Linkou Chang Gung Memorial Hospital, Taipei Mackey
Memorial Hospital, Far Eastern Memorial Hospital, and
China Medical University Hospital in Taiwan, with a pri-
mary complaint of chest pain and who were suspected
of having acute coronary syndrome were recruited into
this study. All enrolled patients were aged 18 years or
older. Inclusion criteria includes: 1) adults ≥18 years of
age and consented to participate in the study group, 2)
admitted to the emergency room due to chest pains or
potential acute coronary syndrome symptoms, 3) symp-
toms unclear or atypical but suspected to be ACS requiring
further electrocardiogram analysis and blood tests. Exclu-
sion criteria includes: 1) Pregnancy, or clinical scenarios
that may cause false positive test results of elevated
Troponin I or BNP, such as skeletal myopathies, or renal in-
sufficiency [7, 8] (defined by creatinine >2.5 mg/dL), 2)
Non-Taiwan residents, patients whose contact information
is unavailable, patients planning to go abroad and thus
would be unavailable for follow-up, and patients who had
already spent more than two hours in the emergency room
reception area, 3) Patients who were transferred from other
hospitals, 4) Cases where written permission could not be
obtained or refused to participate the study, 5) Cases in
whom the symptoms were already confirmed as not the
cause of acute coronary syndrome, including pneumo-
thorax, acute pulmonary embolism, aortic dissection, acute
gastroenterological diseases or chronic obstructive lung dis-
order, 6) Initial electrocardiogram (ECG) had shown ele-
vated ST segment or new LBBB. Subjects with ST elevation
and new left bundle branch block (LBBB) were excluded
since these clearly showed the onset of AMI, and therefore
did not require diagnosis by MCB test systems. Researchers
then examined patients’ medical records and conducted
telephone interviews to identify any subsequent health is-
sues or discomfort experienced within 45 days after diagno-
sis. Within 45 days of treatment, cardiologists diagnosed
patients with one of the following conditions as positive for
acute coronary syndrome: ST-segment elevation myocardial
infarction (STEMI); non-ST segment elevation myocardial
infarction (NSTEMI); sudden cardiac arrest, high-grade
atrioventricular block (AVB) or ventricular arrhythmia with
cardiac catheter-proven coronary occlusion by thrombus
formation; emergency, urgent, or elective revascularization;
and unstable angina. All study participants underwent
cardiac catheter during admission to confirm the diagnosis
of acute coronary syndrome by experienced interven-
tionalists/cardiologists and patients without these con-
ditions were not enrolled in the study.
Biochemical analysis and multi cardiac biomarker panel
test
During the examination, myoglobin, creatine kinase-
myocardial band isoenzyme fraction (CK-MB), troponin I,
and BNP were tested using a MCB CardioProfiler Panel
(Alere, San Diego, CA). Blood (3 ml) was sampled from
each patient using EDTA K2 Vacuette tubes. Next, 0.25 ml
of blood was siphoned from the total sample using a pipette
and placed onto a test panel. The MCB test panel was then
placed into a Triage MeterPro (Alere, San Diego, CA) for
examination, the results of which were automatically dis-
played and printed after 15 min. Data were presented in
quantitative form with continuous variables presented. All
results were blinded to investigators. Biomarker reference
values (CardioProfiler Panel) were as follows: Troponin I >
0.4 ng/mL, CK-MB > 4.3 ng/mL, myoglobin > 107 ng/mL,
and BNP > 100 pg/mL.
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Statistical analysis
Quantitative data were expressed as mean ± standard devi-
ation. Parametric data were compared by t test, and cat-
egorical data were analyzed by the Chi-square test with
Yates’ correction or Fisher’s exact test. Data were analyzed
using SPSS® statistics software (SPSS 11.5; SPSS Inc.,
Chicago, IL, USA). Data were analyzed for sensitivity,
specificity, positive and negative predictive values (PPV
and NPV), and positive and negative likelihood ratios
(LR+ and LR−). All P < 0.05 was considered statistically
significant with two-sided analysis with P < 0.05 was
considered statistically significant.
Results
A total of 290 patients with chest pain were enrolled
in the current study with an average age of 64.5 years.
Of the 290 patients, 146 were elderly (≥65 years),
with an average age of 75.4 years, which represented
50.3 % of the total sample. The remaining 144 pa-
tients were <65 years of age (average age: 53.4 years)
which represented 49.7 % of the total sample. Further,
109 patients were women (71 elderly and 38 young),
and constituted 37.6 % of the total sample (Table 1).
A prior history of cardiovascular diseases (including
prior stroke, myoacrdial infarction, history of coronary
interventions or bypass graft surgery) was reported in
34.5 % of the participants (100/290). Other common co-
morbidities included angina (30 % [87/290]) and coron-
ary angioplasty (22.5 % [54/290]). At baseline, elderly
patients reported statistically significantly more medical
conditions such as myocardial infarction, cardiovascular
disease, heart failure, and stroke, compared with young
patients (p < 0.05).
High blood pressure was found to be the most preva-
lent risk factor in patients with chest pain (60.7 %),
followed by diabetes (30.7 %), and dyslipidemia (30.7 %).
A larger proportion of elderly patients had high blood
pressure and diabetes, while younger patients were
more likely to have dyslipidemia, a family history of
cardiovascular disease, or a history of smoking (Table 1).
A total of 73 (25.2 %) patients were diagnosed with
cardiovascular disease, 35 of which were elderly
(23.9 %) and 38 were young (26.4 %). Using the
MCB approach in the diagnosis of acute coronary
syndrome, young patients demonstrated a higher
relative risk for acute coronary syndrome than elderly
patients (6.25 vs. 3.16) (Table 2). In addition, 20 out
of 109 (18.3 %) women were diagnosed with 53 out
of 181 men (29.3 %). The MCB approach in the
diagnosis of acute coronary syndrome revealed a
higher relative risk in women than in men (6.17 vs.
3.36) (Table 3).
Table 1 The statistics of characters between the elderly group and younger group
Patient’s group
Variables
All Patients ≥65 years Patients <65 years P value
Number 290 146 144
Age (in years) 64.49 ± 13.1 75.4 ± 6.6 53.4 ± 7.6
Female 109 (37.6 %) 71 (48.6 %) 38 (26.4 %)
Cardiovascular Event History
Myocardial infarction 40 (13.8 %) 21 (14.4 %) 19 (13.2 %) 0.41
Angina pectoris 87 (30 %) 44 (30.1 %) 43 (29.9 %) 0.48
Tachycardia 4 (1.4 %) 2 (1.4 %) 2 (1.4 %) 0.49
Cardiovascular diseases* 100 (34.5 %) 57 (39 %) 43 (29.8 %) <0.05
Cardiac arrhythmia 19 (6.5 %) 12 (8.2 %) 7 (4.9 %) 0.18
Congestive heart failure* 15 (5.2 %) 13 (8.9 %) 2 (1.4 %) <0.05
Stroke or temporal ischemia* 20 (6.9 %) 16 (10.9 %) 4 (2.8 %) <0.05
Coronary artery bypass grafting surgery 9 (3.1 %) 6 (4.1 %) 3 (2.1 %) 0.27
Coronary angioplasty 54 (22.5 %) 30 (20.5 %) 24 (16.7 %) 0.35
Risk Factor
High blood pressure* 176 (60.7 %) 103 (70.5 %) 73 (50.7 %) <0.05
Diabetes* 89 (30.7 %) 53 (36.3 %) 36 (25 %) <0.05
Lipidemia* 89 (30.7 %) 36 (24.6 %) 53 (36.8 %) <0.05
Family history of Cardiovascular disease* 68 (23.4 %) 23 (15.7 %) 45 (31.2 %) <0.05
Smoker* 64 (22.1 %) 7 (4.8 %) 57 (39.6 %) <0.05
Data: mean (standard deviation), number (percentage)
*mean P < 0.05
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The MCB tests in the two age groups demonstrated
differences in sensitivity, specificity, and PPV (p < 0.05).
The MCB tests also demonstrated improved sensitivity
(80 %) and NPV (87.5 %) for elderly patients, and higher
specificity (84.9 %) and PPV (55.6 %) for younger pa-
tients. Cardiac biomarkers exhibited a higher positive
likelihood ratio (LR+) in the diagnosis of acute cardio-
vascular syndrome in young patients (3.49 vs. 1.43)
(Table 4).
Differences were also observed in the sensitivity and
PPV of MCB tests across genders. The biomarkers had
higher sensitivity (80 %) and NPV (93.1 %) in female pa-
tients, while the specificity (66.1 %) and PPV (43.4 %)
were higher in male patients. The LR+ diagnosis of acute
coronary syndrome was higher in female patients than
in male patients (2.03 vs. 1.81) (Table 5).
When the efficacy of MCB tests across both age and
gender groups was investigated, MCB tests showed the
highest sensitivity (87.5 %) and negative likelihood ratio
(LR−) in elderly female patients, and the highest specifi-
city (91.2 %), NPV (93.9 %), and LR+ (5.67) in young fe-
male patients (Table 6).
Discussion
Acute coronary syndrome is diagnosed on the basis of
typical angina, electrocardiogram (ECG) results, and car-
diac enzymes analysis. Patients with positive for two out
of the three clinical criteria are diagnosed with acute
coronary syndrome. This study focused on patients who
experienced chest pain and who were suspected of hav-
ing acute coronary syndrome. If the patient demon-
strated ST-segment elevation and LBBB they were
diagnosed with acute coronary syndrome. In such cases,
cardiac enzyme analysis was not necessary. Patients who
experience chest pain without any obvious change in
their electrocardiogram or patients with atypical symp-
toms such as chest tightness, fainting spells, sweating,
and shortness of breath are confounding for clinicians.
In such cases, it is necessary to examine cardiac enzymes
to aid in arriving at the proper diagnosis. Thus, we in-
vestigated the diagnostic efficacy of MCB tests in pa-
tients suspected of having acute coronary syndrome.
Rapid and accurate recognition together with efficient
or rapid service strategy (e.g. same-day transfer) had
been shown to increase the access rate to subsequent
cath-lab management and further reduced hospital stay
length in ACS patients. Based on this, an efficient and
cost-effective diagnostic strategy prior to optimal imple-
mentation of health care model had become a major chal-
lenge in current clinical practice. For example, Campo et al.
proposed a Hub and Spoke model in intermediate-to-high
risk non-ST-segment elevation ACS patients referral, while
other center ever reported [9]. Previous studies have dem-
onstrated the effects of age and gender on the diagnosis of
acute coronary syndrome. The use of electrocardiograms in





≧65 years (N = 146) <65 years (N = 144)
Positive Negative Positive Negative
MCB positive 28 (19.2 %) 62 (42.4 %) 20 (13.9 %) 16 (11.1 %)
MCB negative 7 (4.8 %) 49 (33.5 %) 18 (12.5 %) 90 62.5 %)
Odds ratio 3.161* 6.25*
* mean P < 0.05





Male (N = 181) Female (N = 109)
Positive Negative Positive Negative
Cardiac biomarker
positive
32 (17.6 %) 44 (24.3 %) 16 (14.6 %) 35 (32.1 %)
Cardiac biomarker
negative
21 (11.6 %) 84 (46.4 %) 4 (3.6 %) 54 (49.5 %)
Odds ratio 3.364* 6.171*
* mean P < 0.05
Table 4 Diagnostic Capabilities of MCB tests by Age
Patient of Age P value
Patients ≥65 years Patients <65 years
Sensitivity 80.0 % (64.1–90.0) 52.6 % (37.3–67.5) <0.05*
Specificity 44.1 % (35.3–53.4) 84.9 % (76.9–90.5) <0.05*
PPV 31.1 % (22.5–41.3) 55.6 % (39.6–70.5) <0.05*
NPV 87.5 % (76.4–93.8) 83.3 % (75.2–89.2) 0.28
LR+ 1.43 (1.13–1.81) 3.49 (2.02–6.00)
LR− 0.45 (0.22–0.91) 0.56 (0.39–0.79)
PS: PPV, NPV, LR+ and LR− mean positive and negative predictive values,
positive and negative likelihood ratios, respectively
*mean P < 0.05
Table 5 Diagnostic Capabilities of MCB tests by Gender
Patient of gender P value
Men (N = 181) Women (N = 109)
Sensitivity 61.1 % (47.8–73.0) 80.0 % (58.4–91.9) <0.05*
Specificity 66.1 % (57.5–73.8) 60.7 % (50.3–70.2) 0.23
PPV 43.4 % (32.9–54.6) 31.4 % (20.3–45.0) 0.07
NPV 80 % (71.4–86.5) 93.1 % (83.6–97.3) <0.05*
LR+ 1.81 (1.31–2.49) 2.03 (1.45–2.85)
LR− 0.59 (0.41–0.84) 0.33 (0.14–0.81)
PS: PPV, NPV, LR+ and LR− mean positive and negative predictive values,
positive and negative likelihood ratios, respectively
*mean P < 0.05
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elderly patients can be problematic, such as in cases when
the patient has a pacemaker or relatively low ST-segment
elevation [10]. Elderly patients can exhibit symptoms simi-
lar to myocardial infarction, such as with gastritis or pneu-
monia [11–13]. Further, only a small proportion of elderly
patients with acute coronary syndrome experience typical
angina symptoms [14]. Finally, patients with congestive
heart failure, diabetes, or coronary artery bypass graft sur-
gery may exhibit atypical chest pains [14]. The current
study also demonstrated that elderly patients are likely to
exhibit these atypical factors. In addition, patients who
smoke or have dyslipidemia exhibit relatively typical chest
pain symptom, leading to many cases of acute coronary
syndrome in younger patients [15].
Conventionally, female patients are less likely to seek
for medical help than male patients. In addition, the
symptoms of myocardial ischemia with chest pain are
apparent atypically and easily confused with female chest
wall or breast lesions with pain [15]. A relatively low
proportion of electrocardiograms in women show ST-
segment elevation; thus, the use of biomarkers to analyze
the probability of acute coronary syndrome in women can
help overcome these difficulties in a more efficient man-
ner. This study also demonstrated that young and female
patients have a relatively higher risk of acute coronary
syndrome after positive biodetection.
Troponin I is an important biomarker for diagnosing
acute myocardial infarction due to its sensitivity and
specificity in the detection of cardiomyocyte injury, as
well as its character of remaining detectable in the blood
for a continuous period of 4 days, and up to 2 weeks.
However, there is also a shortcoming for clinical Troponin
I use, for example, it only begins to rise 6 h after disease
onset. However, patients with acute coronary syndrome
will often seek for medical attention shortly after symp-
toms emerge, resulting in a time delay between the clinical
symptoms and diagnostic results. McCord’s et al. has re-
ported that 49 % of patients with acute coronary syn-
drome arrive at the hospital within 4 h of disease onset,
leading to a large number of patients remain undiagnosed
in the emergency room for hours due to the time gap as
mentioned above [16].
According to a joint European Society of Cardiology
(ESC) and American College of Cardiology (ACC) com-
mittee recommendation for diagnostic indicators of
myocardial infarction, the 99th percentile upper range of
troponin I in normal population serves as the recom-
mended critical value for a diagnosis of myocardial infarc-
tion and myocardial damage; however, this may cause
complications for an accurate diagnosis [17]. Although
troponin I demonstrates high specificity, several factors,
including renal failure, sepsis, chest trauma, and anthracy-
cline use, may generate false-positive results due to ele-
vated troponin I levels, resulting in erroneous treatment
and unnecessary hospital stays [18].
In the current study MCB tests had higher specificity
in elderly women than in men (Table 6). In particular,
troponin I showed high specificity in female patients,
which may help to clarify the real disease in a great
portion of women manifested as angina clinically. In
this regard, if a patient presented with abnormal tropo-
nin I value, the possible misclassification as normal or
false negative rate in women can be largely avoided and
can be discharged from ED safely. Studies have shown
that if only cardiac biomarkers are monitored within
the first 6 h of onset of myocardial infarction, they are
unable to provide sufficient diagnostic capability in
terms of sensitivity and specificity [17]. Due to these
aforementioned reasons, patients are unable to receive
accurate diagnoses in a timely fashion, which not only
results in overcrowded emergency rooms but also
causes unnecessary hospital stays and significantly
higher costs [18]. Of the 290 patients recruited in this
study, 18.3 % of the women experienced cardiovascular
events, which is considerably lower than the 29.3 % of
men who experienced a cardiovascular event. Previous
studies have demonstrated that the proportion of
women with abnormal troponin I levels was relatively
low because only approximately 6 % of troponin T and
3 % of troponin I exist in a free-floating state within the
myocardial tissue of female gender. Since men typically
have a greater number of cardiomyocytes than women,
therefore the troponin I levels in men are easier to
monitor or identified [19].
Table 6 Diagnostic Capabilities of MCB tests by Gender and Age
≥65 years old (N = 146) <65 years old (N = 144)
Male (N = 75) Female (N = 71) Male (N = 106) Female (N = 38)
Sensitivity 73.7 % (51.2–88.2) 87.5 % (64–96.5) 52.9 % (36.7–68.5) 50.0 % (15.0–85.0)
Specificity 46.4 % (34.0–59.3) 41.8 % (29.7–55.0) 81.9 % (71.5–89.1) 91.2 % (77.0–97.0)
PPV 31.8 % (20.0–46.6) 30.4 % (19.1–44.8) 58.1 % (40.8–73.6) 40.0 % (11.8–76.9)
NPV 83.9 % (71.1–89.2) 92 % (75.0–97.8) 78.7 % (68.1–86.4) 93.9 % (80.4–98.3)
LR+ 1.37 (0.96–1.98) 1.50 (1.12–2.01) 2.93 (1.63–5.26) 5.67 (1.32–24.37)
LR− 0.57 (0.25–1.26) 0.29 (0.08–1.13) 0.57 (0.39–0.83) 0.55 (0.20–1.47)
PS: PPV, NPV, LR+ and LR− mean positive and negative predictive values, positive and negative likelihood ratios, respectively
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From the perspective of emergency room doctors, a
quick and accurate diagnosis of acute coronary syndrome
in elderly patients with chest pain is a major challenge.
While patients’ medical records and physiology can be
conveniently examined, both these methods have lower
sensitivity and specificity. Although electrocardiograms
are continuously monitored and in general may have a
diagnostic specificity of 92 %, their sensitivity is only 39 %
[20]. Several studies have shown that the use of MCB
tests—such as troponin I, CK-MB, and myoglobin, which
are related to cardiomyocyte necrosis, or BNP, which is re-
lated to cardiomyocyte function—can effectively improve
the risk classification of patients with acute coronary syn-
drome. Due to the traditional shortcomings of individual
biomarkers, the American College of Cardiology recom-
mends that myoglobin be included in our MCB approach
to improve diagnostic capability [21]. Since myoglobin is
commonly present in skeletal muscle and myocardium, its
levels will elevate 1–2 h after ACS symptoms. While myo-
globin has a relatively low specificity, it has a very high
sensitivity. Thus, if myoglobin is added as a biomarker for
the identification of acute coronary syndrome, the diag-
nostic workflow may be executed more quickly and accur-
ately. Of note, the proportion of female gender varied
largely in different age groups (categorized as <, or > =
65 years old) in our current work, which may potentiate
the bias in the results generated.
By using a MCB approach we were able to effectively
identify patients with low-risk chest pain. In particular,
the MCB approach demonstrated excellent diagnostic
capability in female and elderly patients, both of whom
are considered to be challenging in accurate diagnosis.
In our current work, both populations presented with
relatively good sensitivity and NPV (> = 80 %). In par-
ticular, the sensitivity and specificity for elderly female
patients were near 90 %. In light of these findings, we
can not only reduce the amount of time patients spend
in the emergency room but also lessen the burden on at-
tending clinicians.
One study showed that when 1285 emergency room
chest pain patients were monitored for myoglobin, CK-
MB, and troponin I over 90 min, they achieved a NPV
of 100 %. Of the 508 patients who were diagnosed as
negative, only one returned to the emergency room with
myocardial infarction 30 days after the diagnosis [22].
This demonstrates that multiple biomarker tests can ef-
fectively exclude patients with chest pains and potential
acute coronary syndrome. Furthermore, non-myocardial
infarction patients can be excluded when the elevation
of the CK-MB level over 2 h exceeds 1.5 ng/mL or the
troponin I level exceeds 0.2 ng/mL [23].
The current study demonstrates that a MCB approach
is more effective in the evaluation of elderly patients
than young patients. During the process of assessing and
selecting potential groups and excluding potential cases,
the elderly patient group showed high NPV (87.5 %) and
sensitivity (80 %), both of which were statistically signifi-
cant. These results showed that by using the MCB ap-
proach for elderly patients with chest pain, one can
quickly and accurately exclude acute coronary syndrome
and other cardiovascular diseases in 2 h. Thus, the
amount of time patients spend in the emergency room is
reduced and unnecessary hospital stays are avoided. A
recent study showed that a MCB approach can reduce
the amount of time chest pain patients spend in the
emergency room from 1 to 2 days to just 3–4 h [24].
Another study shows that by expediting the diagnostic
process, the MCB approach can also lessen the costs of
treatment for patients with chest pain [25]. Thus, this
tool may aid in reducing emergency room crowding and
minimize subsequent medical expenses [25].
Moreover, by using point-of-care monitoring MCB, we
can speed up report completion time and therefore im-
prove the efficacy of clinical practice. Studies have
shown that as compared with traditional testing, the
reporting time in point-of-care monitoring systems can
be decreased by 75–85 % [26]. Such point-of-care moni-
toring systems are able to aid in expediting diagnosis.
Conclusions
Our results revealed that due to the high sensitivity and
NPV of MCB, the clinical implementation of such diag-
nostic tools can help physicians exclude acute coronary
syndrome quickly and accurately in elderly patients
present with atypical chest pain in the emergency de-
partment. Furthermore, we also demonstrated that MCB
tests are effective in the diagnosis of acute coronary syn-
drome in elderly and female patients. The clinical use of
MCB in high-risk, atypical chest pain or in elderly pa-
tients can therefore facilitate accurate and proper diag-
nosis in a more timely fashion, reduce the time spent in
the emergency room, and expedite treatment delievery.
Finally, MCB tests may enormously improve the clinical
workflow of emergency treatment and effectively reduces
the rates of diagnostic misclassification encountered in
certain challenging patient populations from the emer-
gency room.
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